Trevi Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Trevi Therapeutics announced its third-quarter 2025 financial results, highlighting positive Phase 2b CORAL trial data for Haduvio in IPF chronic cough and progress across its clinical pipeline.
NASDAQ
Trevi Therapeutics announced positive Phase 2b and Phase 2a clinical trial results for Haduvio in chronic cough, extending its cash runway into 2029.
NASDAQ
10-Q: Trevi Therapeutics Reports Q1 2025 Financial Results, Highlights Progress in Chronic Cough Programs
Trevi Therapeutics reports its Q1 2025 financial results, showcasing ongoing clinical trial progress for Haduvio in treating chronic cough related to IPF, non-IPF ILD, and RCC.
NASDAQ
10-Q: Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Clinical Program Update
Trevi Therapeutics reports a net loss of $13.2 million for the third quarter of 2024, while advancing its clinical programs for Haduvio.
NASDAQ
Trevi Therapeutics reports a net loss of $23.3 million for the first half of 2024, while advancing clinical trials for Haduvio.
NASDAQ
10-Q: Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Clinical Program Update
Trevi Therapeutics reports a net loss of $10.9 million for the first quarter of 2024, while advancing its clinical programs for Haduvio.